XTL Biopharmaceuticals to Present at the JPMorgan Small Cap Conference
February 13 2006 - 3:05AM
PR Newswire (US)
NEW YORK, February 13 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals, Ltd. (LSE:XTL)(NASDAQ:XTLB)(TASE:XTL), a
biopharmaceutical company developing drugs against hepatitis,
announced today that Ron Bentsur, Chief Executive Officer, will
present an overview of the Company at The JPMorgan Small Cap
Conference in Philadelphia. Mr. Bentsur's presentation will take
place on Thursday, February 16, 2006 at 9:30 a.m. Eastern Time at
the Four Seasons Hotel. A live audio webcast of Mr. Bentsur's
presentation will be available at
http://equityconferences.jpmorgan.com/. An archived version of the
webcast will be available following the conclusion of the live
presentation. Contact: Ron Bentsur, Chief Executive Officer Tel:
+1-212-531-5971 About XTL Biopharmaceuticals Ltd. XTL
Biopharmaceuticals Ltd. ("XTLbio") is engaged in the research,
development and commercialization of therapeutics for the treatment
of infectious diseases, with a focus on hepatitis C. XTLbio is
developing XTL-2125 - a small molecule, non-nucleoside inhibitor of
the hepatitis C virus polymerase. XTL-2125 is expected to enter
Phase I clinical trial in 1H 2006. XTLbio is also developing
XTL-6865 - a combination of two monoclonal antibodies against the
hepatitis C virus - presently in Phase 1 clinical trials in
patients with chronic hepatitis C. XTLbio's hepatitis C pipeline
also includes several families of pre-clinical hepatitis C small
molecule inhibitors. In addition, XTL has out-licensed to Cubist
Pharmaceuticals an antibody therapeutic against hepatitis B,
HepeX-B, which has recently completed a Phase 2b clinical study in
transplant patients. XTLbio is publicly traded on the London,
NASDAQ, and Tel-Aviv Stock Exchanges (LSE:
XTL)(NASDAQ:XTLB)(TASE:XTL). DATASOURCE: XTL Biopharmaceuticals
Ltd. CONTACT: Ron Bentsur, Chief Executive Officer, Tel:
+1-212-531-5971
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024